Download scoring documents for this measure. BACK FACT-En Scoring Downloads Download DOC

FACT-Ga Functional Assessment of Cancer Therapy – Gastric For patients with Gastric Cancer LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Functional Assessment of Cancer Therapy – Gastric (FACT-Ga) was developed for use in clinical trials and oncology practice to evaluate treatment efficacy from the patient's perspective and to monitor symptom burden over time. It has been validated for its reliability and sensitivity to clinical changes, such as variations in disease stage or physical performance. It is a valid and reliable measurement of QoL in patients with gastric adenocarcinoma, is a useful instrument for QoL assessment in clinical trials, and it also may be useful for the detection of significant changes in the QoL of individual patients. MEASURE NAME: Functional Assessment of Cancer Therapy – Gastric (FACT-Ga) VERSION: 4 NUMBER OF ITEMS: 46 PATIENT POPULATION: Gastric cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Gastric Cancer Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FACIT-AD , FACIT-D , FAIT-F DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-Ga can be obtained by registering for permission. Users are not permitted to translate the FACT-Ga without permission from FACIT.org. Permission from FACIT.org to translate the FACT-Ga may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Garland, S., Pelletier, G., Lawe, A., Biagioni, B., Eliasziw, M., Cella, D., & Bathe, O. Prospective evaluation of the reliability, validity and minimally important difference of the Functional Assessment of Cancer Therapy-Gastric (FACT-Ga) quality of life instrument. Cancer 2011; 117(6): 1301-1312. Zhou, H., So, J., Yong, W., Luo, N., Zhu, F., Naidoo, N., Li, S., & Yeoh, K. Validation of the functional assessment of cancer therapy-gastric module for the Chinese population. Health and Quality of Life Outcomes 2012; 10:145. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACIT-AD Functional Assessment of Chronic Illness Therapy - Abdominal Discomfort LEARN MORE FACIT-D Functional Assessment of Chronic Illness Therapy – Diarrhea LEARN MORE FAIT-F Functional Assessment of Incontinence Therapy – Fecal LEARN MORE

Download this measure in English. BACK NFHSI-18 English Downloads Download PDF Download DOC

NFPSI-17 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Prostate Cancer Symptom Index - 17 Item Version For patients with Prostate cancer; a FACT/NCCN-Prostate Symptom Index LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The NCCN/FACT Prostate Symptom Index-17 is a brief measure that can be used to examine the effectiveness of noncurative treatments in advanced prostate cancer in line with regulatory guidance covering the spectrum of symptoms, side effects, and concerns in clinically advanced prostate cancer. Input from two waves of expert medical providers (n=66 and 11) and two waves of patient engagement and testing (n=50 and 24) resulted in a 17-item symptom index for advanced prostate cancer divided into categories based on whether the symptoms were predominantly disease or treatment related. Reliability estimates suggested good internal consistency (a=0.86) and relationships with expected outside validity criteria. This brief measure can help clinicians and researchers quickly target and measure important symptoms and concerns in advanced prostate cancer. MEASURE NAME: National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Prostate Cancer Symptom Index - 17 Item Version (NFPSI-17) VERSION: 2 NUMBER OF ITEMS: 17 PATIENT POPULATION: Prostate cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Disease-Related Symptoms – Physical, Disease-Related Symptoms – Emotional, Treatment Side-Effects, Function/Well-Being TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. RELATED MEASURES: FACT-P , FPSI , FACT-RNT DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the NFPSI-17 can be obtained by registering for permission. Users are not permitted to translate the NFPSI-17 without permission from FACIT.org. Permission from FACIT.org to translate the NFPSI-17 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Beaumont, J., Butt, Z., Li, R., & Cella, D. Meaningful Differences and Validity for the NCCN/FACT-P Symptom Index: An analysis of the ALSYMPCA data. Cancer 2019; 125(11): 1877-1885. doi: 10.1002/cncr.31973. Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Rosenbloom, S., Yount, S., Yost, K., Hampton, D., Paul, D., Abernethy, A., Jacobsen, P., Syrjala, K., Von Roenn, J., & Cella, D. Development and validation of eleven symptom indices to evaluate response to chemotherapy for advanced cancer: Measurement compliance with regulatory demands. Farquhar, I., Summers, K., Sorkin, A. (Eds.). The Value of Innovation: Impacts on Health, Life Quality and Regulatory Research. Emerald Group Publishing Inc. 2007; 16: 53-66. doi: 10.1016/S0194-3960(08)16003-6. Satapathy, S., Mittal, B., Sood, A. et al. 177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial. Eur J Nucl Med Mol Imaging (2021). https://doi.org/10.1007/s00259-021-05618-3. Satapathy S, Mittal BR, Sood A, Das CK, Singh SK, Mavuduru RS, et al. Health-related quality-of-life outcomes with actinium-225-prostatespecific membrane antigen-617 therapy in patients with heavily pretreated metastatic castration-resistant prostate cancer. Indian J Nucl Med 2020;35:299-304. Victorson, D., Beaumont, J., Rosenbloom, S., Shevrin, D., & Cella, D. Efficient assessment of the most important symptoms in advanced prostate cancer: The NCCN/FACT-P symptom index. Psycho-Oncology 2011; 20(9): 977-983. doi: 10.1002/pon.1817. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-P Functional Assessment of Cancer Therapy – Prostate LEARN MORE FPSI Functional Assessment of Cancer Therapy Prostate Cancer Symptom Index - 7 Item Version LEARN MORE FACT-RNT Functional Assessment of Cancer Therapy – Radionuclide Therapy LEARN MORE

Download this measure in English. BACK PRRS English Downloads Download PDF Download DOC

View all available languages for this measure. BACK FAIT-F Languages English German

MICRA Multidimensional Impact of Cancer Risk Assessment For patients who have undergone genetic testing for risk of cancer LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Multidimensional Impact of Cancer Risk Assessment (MICRA) is a tool to measure the specific impact of result disclosure after genetic testing. The authors compared its performance with that of questionnaires measuring general and cancer-specific distress. Participants (158 females) responded 1 month after they received genetic test results. They were divided into 4 standard clinical test result groups: BRCA1/2 positive, BRCA1/2 negative, panel negative, and true negative. Factor analysis supported the formation of 3 subscales: Distress, Uncertainty, and Positive Experiences. All 3 MICRA subscales differentiated participants who were BRCA1/2 positive from the other 3 groups. MICRA thus helps identify subgroups of vulnerable genetic testing participants. MEASURE NAME: Multidimensional Impact of Cancer Risk Assessment (MICRA) VERSION: 1 NUMBER OF ITEMS: 25 PATIENT POPULATION: Patients 18 years and older who have received cancer-related genetic testing RECALL PERIOD: Past 7 days RESPONSE SCALE: 4 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Distress, Uncertainty, Positive Experiences TIME FOR COMPLETION: Not available SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. RELATED MEASURES: FACT-G , FACT-G7 , FANLTC DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the MICRA can be obtained when licensing the measure. Users are not permitted to translate the MICRA without prior permission from FACIT.org. Permission may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor of the MICRA. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cella D, Hughes C, Peterman A, Chang CH, Peshkin BN, Schwartz MD, Wenzel L, Lemke A, Marcus AC, Lerman C. A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychol . 2002 Nov;21(6):564-72. LICENSE THIS MEASURE Related Measures Related Measures FACT-G Functional Assessment of Cancer Therapy - General LEARN MORE FACT-G7 Functional Assessment of Cancer Therapy – General – 7 Item Version LEARN MORE FANLTC Functional Assessment of Non-Life Threatening Conditions LEARN MORE

View all available languages for this measure. BACK FACT-Cx Languages Chinese – Simplified Chinese – Traditional Czech Dutch English French German Hebrew Hindi Italian Japanese Korean Norwegian Portuguese Russian Serbian Spanish Swahili Swedish Thai Turkish Vietnamese

View all available languages for this measure. BACK PROMIS SF v1.0-Dyspnea-Functional Limitations 5b Languages Arabic Afrikaans Bengali Bulgarian Chinese - Simplified Chinese - Traditional Czech Danish Dutch English Finnish French German Greek Gujarati Hebrew Hindi Hungarian Italian Japanese Kannada Korean Malay Malayalam Marathi Norwegian Polish Portuguese Punjabi Romanian Russian Serbian Slovak Slovene Spanish Swedish Tagalog Tamil Telugu Thai Turkish Ukrainian Urdu Xhosa Zulu

Download scoring documents for this measure. BACK FACIT-TS-G Scoring Downloads Download DOC

FACIT-Sp-Ex Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being Expanded Version LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACIT-Sp-Ex measure: MEASURE NAME: Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being Expanded Version (FACIT-Sp-Ex) VERSION: 4 NUMBER OF ITEMS: 23 PATIENT POPULATION: Patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Spiritual Well-Being Expanded Subscale TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FACIT-Sp , FACIT-Sp-12 , FACIT-Pal DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACIT-SP-EX can be obtained by registering for permission. Users are not permitted to translate the FACIT-SP-EX without permission from FACIT.org. Permission from FACIT.org to translate the FACIT-SP-EX may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Bormann, J., Aschbacher, K., Wetherell, J., Roesch, S., & Redwine., L. Effects of faith/assurance on cortisol levels are enhanced by a spiritual mantram intervention in adults with HIV: A randomized trial. Journal of Psychosomatic Research 2009; 66: 161–171. doi: 10.1016/j.jpsychores.2008.09.017. Bormann, J., Gifford, A., Shively, M., Smith, T., Redwine, L., Kelly, A., Becker, S., Gershwin, M., Bone, P., & Belding, W. Effects of Spiritual Mantram Repetition on HIV Outcomes: A Randomized Controlled Trial. Journal of Behavioral Medicine 2006; 29(4): 359-376. doi: 10.1007/s10865-006-9063-6. Murphy, P., Canada, A., Fitchett, G., Stein, K., Portier, K., Crammer, C., & Peterman, A. An examination of the 3-factor model and structural invariance across racial/ethnic groups for the FACIT-Sp: a report from the American Cancer Society’s Study of Cancer Survivors-II (SCS-II). Psycho-Oncology 2010; 19: 264–272. doi: 10.1002/pon.1559. Trevino, K., Pargament, K., Cotton, S., Leonard. A., Hahn, J., Caprini-Faigin, C., & Tsevat, J. Religious Coping and Physiological, Psychological, Social, and Spiritual Outcomes in Patients with HIV/AIDS: Cross-sectional and Longitudinal Findings. AIDS and Behavior 2010; 14: 379-389. doi: 10.1007/s10461-007-9332-6. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACIT-Sp Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being LEARN MORE FACIT-Sp-12 Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale LEARN MORE FACIT-Pal Functional Assessment of Chronic Illness Therapy - Palliative Care LEARN MORE

Download scoring documents for this measure. BACK FACIT-Item GP5 Scoring Downloads Single item score, no scoring template